Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H2 2017’, provides an overview of the Keratoconjunctivitis sicca (Dry Eye) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis sicca (Dry Eye), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye)

The report reviews pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Keratoconjunctivitis sicca (Dry Eye) therapeutics and enlists all their major and minor projects

The report assesses Keratoconjunctivitis sicca (Dry Eye) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Alcon Laboratories Inc

Aldeyra Therapeutics Inc

Allergan Plc

Ascendia Pharmaceuticals LLC

BioLineRx Ltd

Cambium Medical Technologies LLC

Chong Kun Dang Pharmaceutical Corp

Clementia Pharmaceuticals Inc

Dompe Farmaceutici SpA

Elasmogen Ltd

HanAll Biopharma Co Ltd

Herantis Pharma Plc

Huons Global Co Ltd

InSite Vision Inc

Kala Pharmaceuticals Inc

KPI Therapeutics Inc

Kukje Pharmaceutical Industry Co Ltd

Laboratoires Thea SA

Lipicard Technologies Ltd

Merck & Co Inc

Mitotech SA

Nanomerics Ltd

Nemus Bioscience Inc

Novaliq GmbH

Ocular Therapeutix Inc

Oculis ehf

OncoNOx ApS

Otsuka Holdings Co Ltd

Quorum Innovations LLC

Redwood Pharma AB

RegeneRx Biopharmaceuticals Inc

Samjin Pharm Co Ltd

Santen Pharmaceutical Co Ltd

Seikagaku Corp

Shire Plc

Sun Pharma Advanced Research Company Ltd

Sylentis SAU

TearSolutions LLC

TopiVert Ltd

Vanda Pharmaceuticals Inc

Xigen SA

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Keratoconjunctivitis sicca (Dry Eye) - Overview 9

Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Development 10

Pipeline Overview 10

Pipeline by Companies 11

Pipeline by Universities/Institutes 15

Products under Development by Companies 16

Products under Development by Universities/Institutes 20

Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Assessment 21

Assessment by Target 21

Assessment by Mechanism of Action 24

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Keratoconjunctivitis sicca (Dry Eye) - Companies Involved in Therapeutics Development 31

Alcon Laboratories Inc 31

Aldeyra Therapeutics Inc 31

Allergan Plc 31

Ascendia Pharmaceuticals LLC 32

BioLineRx Ltd 32

Cambium Medical Technologies LLC 33

Chong Kun Dang Pharmaceutical Corp 33

Clementia Pharmaceuticals Inc 34

Dompe Farmaceutici SpA 34

Elasmogen Ltd 34

HanAll Biopharma Co Ltd 35

Herantis Pharma Plc 35

Huons Global Co Ltd 36

InSite Vision Inc 36

Kala Pharmaceuticals Inc 37

KPI Therapeutics Inc 37

Kukje Pharmaceutical Industry Co Ltd 37

Laboratoires Thea SA 38

Lipicard Technologies Ltd 38

Merck & Co Inc 38

Mitotech SA 39

Nanomerics Ltd 39

Nemus Bioscience Inc 40

Novaliq GmbH 40

Ocular Therapeutix Inc 40

Oculis ehf 41

OncoNOx ApS 41

Otsuka Holdings Co Ltd 42

Quorum Innovations LLC 42

Redwood Pharma AB 43

RegeneRx Biopharmaceuticals Inc 43

Samjin Pharm Co Ltd 44

Santen Pharmaceutical Co Ltd 44

Seikagaku Corp 45

Shire Plc 45

Sun Pharma Advanced Research Company Ltd 46

Sylentis SAU 46

TearSolutions LLC 46

TopiVert Ltd 47

Vanda Pharmaceuticals Inc 47

Xigen SA 48

Keratoconjunctivitis sicca (Dry Eye) - Drug Profiles 49

ADP-355 - Drug Profile 49

ADP-399 - Drug Profile 50

ADX-102 - Drug Profile 51

ADX-103 - Drug Profile 57

AGN-223575 - Drug Profile 58

AGN-232411 - Drug Profile 59

AL-41A1 - Drug Profile 60

AVA-3486 - Drug Profile 61

AVX-012 - Drug Profile 62

AX-1606 - Drug Profile 63

BL-1230 - Drug Profile 64

BRM-421 - Drug Profile 65

cenegermin - Drug Profile 66

cinhyaluronate sodium - Drug Profile 69

Cis-Urocanic Acid - Drug Profile 70

cyclosporine - Drug Profile 72

cyclosporine - Drug Profile 75

cyclosporine - Drug Profile 77

cyclosporine - Drug Profile 78

cyclosporine - Drug Profile 79

cyclosporine - Drug Profile 80

cyclosporine - Drug Profile 81

cyclosporine SR - Drug Profile 82

dexamethasone acetate SR - Drug Profile 83

diclofenac sodium - Drug Profile 91

diquafosol tetrasodium - Drug Profile 92

Drug for Dry Eye - Drug Profile 94

ECF-843 - Drug Profile 95

Elate Ocular - Drug Profile 97

ELN-22 - Drug Profile 98

HL-036 - Drug Profile 99

HU-007 - Drug Profile 100

hyaluronate sodium - Drug Profile 101

ISV-101 - Drug Profile 102

K-089 - Drug Profile 103

KeraKlear - Drug Profile 104

KJ-14003 - Drug Profile 105

KJ-16001 - Drug Profile 106

KPI-190 - Drug Profile 107

Lacripep - Drug Profile 108

Leukothera - Drug Profile 109

lifitegrast - Drug Profile 111

LME-636 - Drug Profile 116

loteprednol etabonate - Drug Profile 117

LT-4003 - Drug Profile 120

NB-2222 - Drug Profile 121

Nov-03 - Drug Profile 122

Nov-07 - Drug Profile 123

OC-301 - Drug Profile 124

OCX-071 - Drug Profile 125

OTX-101 - Drug Profile 126

OX-1001 - Drug Profile 128

palovarotene - Drug Profile 129

plastoquinone decyl triphenylphosphonium bromide - Drug Profile 136

PPL-003 - Drug Profile 138

Protearin - Drug Profile 140

Qi-401 - Drug Profile 141

rebamipide - Drug Profile 142

RGN-259 - Drug Profile 144

RP-101 - Drug Profile 151

SA-001 - Drug Profile 153

SHP-659 - Drug Profile 154

SJP-002 - Drug Profile 156

solithromycin - Drug Profile 157

ST-266 - Drug Profile 171

Stem Cell Therapy for Cardiovascular, Central Nervous System, Mouth and Dental Disorders, Ophthalmology and Respiratory Disorders - Drug Profile 173

SYL-1001 - Drug Profile 175

tadekinig alfa - Drug Profile 177

TOP-1630 - Drug Profile 179

XG-104 - Drug Profile 181

zucapsaicin - Drug Profile 182

Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects 184

Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products 188

Keratoconjunctivitis sicca (Dry Eye) - Product Development Milestones 189

Featured News & Press Releases 189

Appendix 196

Methodology 196

Coverage 196

Secondary Research 196

Primary Research 196

Expert Panel Validation 196

Contact Us 196

Disclaimer 197

List of Tables

List of Tables

Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Alcon Laboratories Inc, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Aldeyra Therapeutics Inc, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Allergan Plc, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Ascendia Pharmaceuticals LLC, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by BioLineRx Ltd, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Cambium Medical Technologies LLC, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Clementia Pharmaceuticals Inc, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Dompe Farmaceutici SpA, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Elasmogen Ltd, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by HanAll Biopharma Co Ltd, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Herantis Pharma Plc, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Huons Global Co Ltd, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by InSite Vision Inc, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Kala Pharmaceuticals Inc, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by KPI Therapeutics Inc, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Kukje Pharmaceutical Industry Co Ltd, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Laboratoires Thea SA, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Lipicard Technologies Ltd, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Merck & Co Inc, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Mitotech SA, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Nanomerics Ltd, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Nemus Bioscience Inc, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Novaliq GmbH, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Ocular Therapeutix Inc, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Oculis ehf, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by OncoNOx ApS, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Otsuka Holdings Co Ltd, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Quorum Innovations LLC, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Redwood Pharma AB, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Samjin Pharm Co Ltd, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Santen Pharmaceutical Co Ltd, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Seikagaku Corp, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Shire Plc, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Sylentis SAU, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by TearSolutions LLC, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by TopiVert Ltd, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Vanda Pharmaceuticals Inc, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Pipeline by Xigen SA, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Dormant Projects, H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Dormant Projects, H2 2017 (Contd..1), H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Dormant Projects, H2 2017 (Contd..2), H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Dormant Projects, H2 2017 (Contd..3), H2 2017

Keratoconjunctivitis sicca (Dry Eye) – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports